Boston Scientific (BSX) Financials

$106.74 +1.33 (+1.26%)

Closing price 08/4/2025 03:59 PM Eastern

Extended Trading

$106.50 -0.24 (-0.23%)

As of 08/4/2025 07:59 PM Eastern

Annual Income Statements for Boston Scientific

This table shows Boston Scientific's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-239	347	104	1,671	4,700	-115	985	642	1,570	1,853
Consolidated Net Income / (Loss)	-239	347	104	1,671	4,700	-82	1,041	698	1,592	1,846
Net Income / (Loss) Continuing Operations	-239	347	105	1,671	4,700	-81	1,040	698	1,592	1,846
Total Pre-Tax Income	-650	177	933	1,422	687	-79	1,076	1,141	1,985	2,282
Total Operating Income	-283	447	1,285	1,506	1,518	-80	1,199	1,649	2,343	2,603
Total Gross Profit	5,304	5,962	6,455	7,011	7,620	6,448	8,177	8,727	9,896	11,490
Total Revenue	7,477	8,386	9,048	9,823	10,735	9,913	11,888	12,682	14,240	16,747
Operating Revenue	7,477	8,386	9,048	9,823	10,735	9,913	11,888	12,682	14,240	16,747
Total Cost of Revenue	2,173	2,424	2,593	2,813	3,116	3,465	3,711	3,956	4,345	5,257
Operating Cost of Revenue	2,173	2,424	2,593	2,813	3,116	3,465	3,711	3,956	4,345	5,257
Total Operating Expenses	5,587	5,515	5,170	5,504	6,102	6,528	6,978	7,079	7,552	8,887
Selling, General & Admin Expense	2,873	3,099	3,294	3,569	3,941	3,787	4,359	4,520	5,190	5,984
Research & Development Expense	876	920	997	1,113	1,174	1,143	1,204	1,323	1,414	1,615
Amortization Expense	495	545	565	599	699	789	741	803	828	856
Other Operating Expenses / (Income)	70	79	68	70	65	45	-29	69	46	33
Impairment Charge	19	11	4.00	35	105	533	370	132	58	386
Restructuring Charge	26	28	37	36	38	52	40	24	69	16
Other Special Charges / (Income)	1,228	833	205	82	80	178	294	208	-53	-5.00
Total Other Income / (Expense), net	-367	-270	-353	-85	-831	1.00	-123	-508	-358	-305
Interest Expense	284	233	229	241	473	361	341	470	265	305
Income Tax Expense	-411	-170	828	-249	-4,013	2.00	36	443	393	436
Preferred Stock Dividends Declared	-	-	-	0.00	0.00	33	55	55	23	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	-	-	-	-	0.00	0.00	-1.00	-8.00
Basic Earnings per Share	($0.18)	$0.26	$0.08	$1.21	$3.38	($0.08)	$0.69	$0.45	$1.08	$1.26
Weighted Average Basic Shares Outstanding	1.34B	1.36B	1.37B	1.38B	1.39B	1.42B	1.42B	1.43B	1.45B	1.47B
Diluted Earnings per Share	($0.18)	$0.25	$0.08	$1.19	$3.33	($0.08)	$0.69	$0.45	$1.07	$1.25
Weighted Average Diluted Shares Outstanding	1.34B	1.38B	1.39B	1.40B	1.41B	1.42B	1.43B	1.44B	1.46B	1.49B
Weighted Average Basic & Diluted Shares Outstanding	1.33B	1.33B	1.37B	1.38B	1.40B	1.42B	1.43B	1.43B	1.47B	1.48B

This table shows Boston Scientific's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	174	126	300	261	505	504	495	324	469	565	674
Consolidated Net Income / (Loss)	188	140	314	270	504	504	493	322	468	563	672
Net Income / (Loss) Continuing Operations	188	139	313	270	505	504	493	322	469	562	672
Total Pre-Tax Income	245	395	444	426	610	505	608	420	669	585	805
Total Operating Income	358	402	552	514	693	584	675	520	733	675	921
Total Gross Profit	2,191	2,232	2,349	2,542	2,426	2,579	2,648	2,850	2,897	3,095	3,210
Total Revenue	3,170	3,242	3,389	3,599	3,527	3,725	3,856	4,120	4,209	4,562	4,663
Operating Revenue	3,170	3,242	3,389	3,599	3,527	3,725	3,856	4,120	4,209	4,562	4,663
Total Cost of Revenue	979	1,011	1,040	1,058	1,101	1,146	1,209	1,270	1,312	1,466	1,453
Operating Cost of Revenue	979	1,011	1,040	1,058	1,101	1,146	1,209	1,270	1,312	1,466	1,453
Total Operating Expenses	1,833	1,831	1,797	2,028	1,733	1,994	1,973	2,330	2,164	2,420	2,288
Selling, General & Admin Expense	1,132	1,163	1,215	1,354	1,242	1,379	1,364	1,446	1,562	1,612	1,597
Research & Development Expense	339	330	337	359	356	362	366	383	407	459	443
Amortization Expense	202	199	203	210	208	207	214	213	205	224	219
Other Operating Expenses / (Income)	11	35	11	12	11	12	10	9.00	5.00	9.00	14
Restructuring Charge	4.00	5.00	20	16	15	18	3.00	1.00	8.00	4.00	10
Other Special Charges / (Income)	20	98	12	19	-99	15	17	2.00	-23	-1.00	5.00
Total Other Income / (Expense), net	-114	-6.00	-108	-88	-84	-78	-67	-100	-65	-73	-116
Interest Expense	63	64	65	70	66	64	69	77	79	80	82
Other Income / (Expense), net	-51	58	-43	-18	-18	-14	2.00	-23	14	-	-34
Income Tax Expense	57	256	131	156	105	1.00	115	98	200	23	133
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	-	0.00	0.00	0.00	-1.00	1.00	-2.00	0.00	-7.00	-2.00
Basic Earnings per Share	$0.12	$0.09	$0.21	$0.18	$0.34	$0.35	$0.34	$0.22	$0.32	$0.38	$0.46
Weighted Average Basic Shares Outstanding	1.43B	1.43B	1.44B	1.45B	1.46B	1.45B	1.47B	1.47B	1.47B	1.47B	1.48B
Diluted Earnings per Share	$0.12	$0.09	$0.21	$0.18	$0.34	$0.34	$0.33	$0.22	$0.32	$0.38	$0.45
Weighted Average Diluted Shares Outstanding	1.44B	1.44B	1.45B	1.46B	1.48B	1.46B	1.48B	1.48B	1.49B	1.49B	1.49B
Weighted Average Basic & Diluted Shares Outstanding	1.43B	1.43B	1.44B	1.46B	1.46B	1.47B	1.47B	1.47B	1.47B	1.48B	1.48B

This table details how cash moves in and out of Boston Scientific's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-223	87	530	-187	-232	1,388	173	-1,042	-70	-450
Net Cash From Operating Activities	691	1,182	1,426	310	1,836	1,508	1,870	1,526	2,503	3,435
Net Cash From Continuing Operating Activities	691	1,182	1,426	311	1,838	1,508	1,871	1,527	2,504	3,434
Net Income / (Loss) Continuing Operations	-239	347	104	1,671	4,700	-82	1,041	698	1,592	1,846
Consolidated Net Income / (Loss)	-239	347	104	1,671	4,700	-82	1,041	698	1,592	1,846
Depreciation Expense	769	815	844	894	1,011	1,123	1,093	1,136	1,196	1,269
Amortization Expense	36	22	10	6.00	46	58	34	32	6.00	51
Non-Cash Adjustments To Reconcile Net Income	331	68	237	-91	713	432	-24	541	407	656
Changes in Operating Assets and Liabilities, net	-206	-70	231	-2,169	-4,632	-23	-273	-880	-697	-388
Net Cash From Investing Activities	-2,186	-887	-1,010	-1,921	-5,041	-411	-1,596	-2,011	-2,574	-5,687
Net Cash From Continuing Investing Activities	-2,186	-887	-1,010	-1,922	-5,042	-411	-1,596	-2,011	-2,575	-5,687
Purchase of Property, Plant & Equipment	-247	-376	-319	-316	-461	-376	-554	-588	-711	-790
Acquisitions	-1,734	-408	-560	-1,448	-4,382	-3.00	-2,258	-1,542	-1,811	-4,640
Purchase of Investments	-266	-132	-131	-172	-348	-146	279	32	-87	-280
Sale of Property, Plant & Equipment	0.00	29	0.00	14	7.00	12	14	12	4.00	3.00
Divestitures	-	-	0.00	0.00	90	15	826	5.00	0.00	0.00
Other Investing Activities, net	-	-	0.00	0.00	52	87	82	70	30	20
Net Cash From Financing Activities	1,276	-206	110	1,432	2,973	293	-95	-548	5.00	1,814
Net Cash From Continuing Financing Activities	1,277	-206	110	1,431	2,973	294	-95	-547	5.00	1,813
Repayment of Debt	-1,715	-820	-3,216	-1,171	-5,135	-6,843	0.00	-3,435	-4.00	-317
Payment of Dividends	-	-	-	0.00	0.00	-28	-55	-55	-28	0.00
Issuance of Debt	3,100	630	3,339	2,576	7,929	5,844	0.00	3,270	0.00	2,169
Issuance of Common Equity	114	111	85	101	123	1,086	110	136	182	230
Other Financing Activities, net	-222	-127	-98	-75	56	-205	-150	-463	-145	-269
Effect of Exchange Rate Changes	-4.00	-2.00	4.00	-8.00	-	-2.00	-6.00	-9.00	-4.00	-11
Cash Interest Paid	283	233	235	262	449	359	338	450	259	250
Cash Income Taxes Paid	80	94	42	1,037	242	207	302	662	512	656

This table details how cash moves in and out of Boston Scientific's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	40	628	-363	-142	512	-77	1,441	565	-412	-2,044	314
Net Cash From Operating Activities	470	807	190	658	698	957	164	813	1,002	1,456	541
Net Cash From Continuing Operating Activities	472	807	193	656	697	958	163	813	1,004	1,454	541
Net Income / (Loss) Continuing Operations	188	140	314	270	504	504	493	322	469	562	672
Consolidated Net Income / (Loss)	188	140	314	270	504	504	493	322	469	562	672
Depreciation Expense	284	294	285	298	300	313	304	311	306	348	325
Amortization Expense	7.00	-	-	-	3.00	-	-	-	-	51	81
Non-Cash Adjustments To Reconcile Net Income	205	6.00	117	76	56	158	113	377	49	117	148
Changes in Operating Assets and Liabilities, net	-212	367	-523	9.00	-166	-17	-747	-197	180	376	-685
Net Cash From Investing Activities	-225	-183	-484	-840	-197	-1,053	-285	-271	-1,427	-3,704	-500
Net Cash From Continuing Investing Activities	-223	-182	-484	-840	-198	-1,053	-284	-272	-1,426	-3,705	-500
Purchase of Property, Plant & Equipment	-150	-212	-111	-143	-190	-267	-179	-155	-179	-277	-187
Acquisitions	-71	-	-375	-643	-	-793	-47	-48	-1,127	-3,418	-239
Purchase of Investments	-21	7.00	-10	-63	-16	2.00	-66	-73	-125	-16	-77
Other Investing Activities, net	18	16	9.00	7.00	7.00	7.00	7.00	4.00	5.00	4.00	3.00
Net Cash From Financing Activities	-199	1.00	-69	43	16	15	1,569	24	7.00	214	233
Net Cash From Continuing Financing Activities	-200	2.00	-69	43	16	15	1,569	24	7.00	213	234
Repayment of Debt	-155	-	0.00	37	-41	-	-504	-	-	187	-1,275
Issuance of Debt	-	-	0.00	-	-	-	2,145	-	22	2.00	1,558
Issuance of Common Equity	59	19	63	27	75	17	80	26	96	28	115
Other Financing Activities, net	-90	-4.00	-118	-7.00	-18	-2.00	-152	-2.00	-111	-4.00	-164
Effect of Exchange Rate Changes	-6.00	3.00	0.00	-3.00	-5.00	4.00	-7.00	-1.00	6.00	-9.00	39

This table presents Boston Scientific's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	18,133	18,096	19,042	20,999	30,565	30,777	32,229	32,469	35,136	39,395
Total Current Assets	3,471	3,239	3,822	4,003	4,699	6,694	6,317	5,760	6,514	6,920
Cash & Equivalents	319	196	188	146	217	1,734	1,925	928	865	414
Note & Lease Receivable	1,275	1,472	1,548	1,608	1,828	1,531	1,778	1,970	2,228	2,558
Inventories, net	1,016	955	1,078	1,166	1,579	1,351	1,610	1,867	2,484	2,810
Prepaid Expenses	365	541	942	921	880	751	799	731	621	831
Current Deferred & Refundable Income Taxes	496	75	66	161	195	194	205	264	315	307
Plant, Property, & Equipment, net	1,490	1,630	1,697	1,782	2,079	2,084	2,252	2,446	2,859	3,294
Total Noncurrent Assets	13,172	13,227	13,523	15,216	23,787	21,999	23,661	24,264	25,762	29,182
Goodwill	6,473	6,678	6,998	7,911	10,176	9,951	11,988	12,920	14,387	17,089
Intangible Assets	6,194	5,883	5,837	6,372	7,886	5,917	6,121	5,902	6,003	6,684
Noncurrent Deferred & Refundable Income Taxes	-	-	-	87	4,196	4,210	4,142	3,942	3,841	3,655
Other Noncurrent Operating Assets	505	666	688	846	1,529	1,921	1,410	1,500	1,531	1,754
Total Liabilities & Shareholders' Equity	18,133	18,096	19,042	20,999	30,565	30,777	32,229	32,469	35,136	39,395
Total Liabilities	11,813	11,363	12,030	12,273	16,688	15,450	15,608	14,897	15,605	17,392
Total Current Liabilities	2,430	3,587	5,654	5,260	4,866	3,681	4,274	3,803	4,933	6,399
Short-Term Debt	3.00	64	1,801	2,253	1,416	13	261	20	531	1,778
Accounts Payable	209	447	530	349	542	513	794	862	942	960
Accrued Expenses	1,970	2,312	2,456	2,246	2,109	2,197	2,436	2,160	2,646	2,773
Other Current Liabilities	248	764	867	412	800	958	783	761	814	887
Total Noncurrent Liabilities	9,383	7,776	6,376	7,013	11,822	11,769	11,334	11,094	10,672	10,993
Long-Term Debt	5,674	5,420	3,815	4,803	8,592	9,130	8,804	8,915	8,571	8,968
Noncurrent Deferred & Payable Income Tax Liabilities	735	18	191	328	595	330	310	144	134	155
Other Noncurrent Operating Liabilities	2,974	2,338	2,370	1,882	2,635	2,309	2,220	2,035	1,967	1,870
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	6,320	6,733	7,012	8,726	13,877	15,326	16,622	17,573	19,530	22,003
Total Preferred & Common Equity	6,320	6,733	7,011	8,726	13,877	15,337	16,623	17,573	19,282	21,770
Preferred Stock	0.00	0.00	0.00	0.00	0.00	10	0.00	0.00	0.00	0.00
Total Common Equity	6,320	6,733	7,011	8,726	13,877	15,327	16,623	17,574	19,281	21,770
Common Stock	16,876	17,030	17,177	17,362	17,577	19,749	20,003	20,306	20,664	21,073
Retained Earnings	-8,927	-8,581	-8,390	-6,953	-2,253	-2,378	-1,392	-750	819	2,673
Treasury Stock	-1,717	-1,717	-1,717	-1,717	-1,717	-2,251	-2,251	-2,251	-2,251	-2,251
Accumulated Other Comprehensive Income / (Loss)	88	1.00	-59	33	270	207	263	269	49	275
Noncontrolling Interest	-	-	-	-	-	-	-	0.00	248	233

This table presents Boston Scientific's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Total Assets	31,947	32,469	32,892	33,601	34,043	35,136	36,669	37,108	38,078	39,395	40,140
Total Current Assets	5,144	5,760	5,704	5,886	6,504	6,514	8,185	8,991	8,761	6,920	7,335
Cash & Equivalents	338	928	570	426	952	865	2,329	2,913	2,502	414	725
Note & Lease Receivable	1,871	1,970	2,076	2,134	2,101	2,228	2,304	2,400	2,501	2,558	2,693
Inventories, net	1,788	1,867	2,050	2,250	2,404	2,484	2,561	2,608	2,753	2,810	2,867
Prepaid Expenses	884	731	711	773	741	621	671	756	674	831	756
Current Deferred & Refundable Income Taxes	262	264	296	303	307	315	319	315	332	307	294
Plant, Property, & Equipment, net	2,273	2,446	2,478	2,534	2,635	2,859	2,897	2,951	3,072	3,294	3,389
Total Noncurrent Assets	24,530	24,264	24,711	25,182	24,902	25,762	25,588	25,166	26,245	29,182	29,416
Goodwill	12,852	12,920	13,269	13,659	13,608	14,387	14,361	14,397	15,033	17,089	17,340
Intangible Assets	6,058	5,902	6,060	6,063	5,849	6,003	5,839	5,417	5,754	6,684	6,566
Noncurrent Deferred & Refundable Income Taxes	4,018	3,942	3,900	3,865	3,840	3,841	3,792	3,801	3,816	3,655	3,676
Other Noncurrent Operating Assets	1,602	1,500	1,482	1,595	1,605	1,531	1,596	1,551	1,642	1,754	1,834
Total Liabilities & Shareholders' Equity	31,947	32,469	32,892	33,601	34,043	35,136	36,669	37,108	38,078	39,395	40,140
Total Liabilities	14,307	14,897	14,783	15,117	14,914	15,605	16,501	16,499	17,122	17,392	17,694
Total Current Liabilities	3,549	3,803	4,083	4,562	4,579	4,933	4,916	5,576	5,910	6,399	5,058
Short-Term Debt	20	20	510	559	513	531	1,085	1,580	1,652	1,778	777
Accounts Payable	803	862	868	899	929	942	921	906	907	960	1,004
Accrued Expenses	1,974	2,160	1,918	2,164	2,255	2,646	2,083	2,320	2,460	2,773	2,354
Other Current Liabilities	752	761	787	940	882	814	827	770	891	887	923
Total Noncurrent Liabilities	10,758	11,094	10,700	10,555	10,335	10,672	11,585	10,923	11,212	10,993	12,636
Long-Term Debt	8,564	8,915	8,495	8,494	8,386	8,571	9,534	8,991	9,233	8,968	10,532
Noncurrent Deferred & Payable Income Tax Liabilities	278	144	210	135	91	134	132	132	138	155	158
Other Noncurrent Operating Liabilities	1,916	2,035	1,995	1,926	1,858	1,967	1,919	1,800	1,841	1,870	1,946
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	17,640	17,573	18,109	18,485	19,129	19,530	20,168	20,609	20,956	22,003	22,446
Total Preferred & Common Equity	17,641	17,573	17,850	18,226	18,886	19,282	19,926	20,371	20,708	21,770	22,212
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	17,641	17,574	17,850	18,226	18,885	19,281	19,925	20,372	20,708	21,770	22,212
Common Stock	20,236	20,306	20,373	20,458	20,590	20,664	20,730	20,820	20,980	21,073	21,144
Retained Earnings	-876	-750	-450	-189	315	819	1,314	1,639	2,107	2,673	3,347
Treasury Stock	-2,251	-2,251	-2,251	-2,251	-2,251	-2,251	-2,251	-2,251	-2,251	-2,251	-2,251
Accumulated Other Comprehensive Income / (Loss)	532	269	178	208	231	49	132	164	-128	275	-28
Noncontrolling Interest	-	0.00	259	259	243	248	242	238	248	233	233

This table displays calculated financial ratios and metrics derived from Boston Scientific's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	1.31%	12.16%	7.89%	8.57%	9.28%	-7.66%	19.92%	6.68%	12.29%	17.61%
EBITDA Growth	-0.45%	184.05%	61.59%	27.15%	-13.47%	-34.01%	73.89%	9.24%	24.22%	13.64%
EBIT Growth	-24.91%	212.02%	183.17%	43.15%	-30.20%	-75.69%	402.48%	13.69%	39.66%	15.69%
NOPAT Growth	5.98%	542.36%	-83.50%	1,123.75%	486.83%	-100.54%	2,169.44%	-12.95%	86.28%	12.06%
Net Income Growth	-100.84%	245.19%	-70.03%	1,506.73%	181.27%	-101.74%	1,369.51%	-32.95%	128.08%	15.95%
EPS Growth	-100.00%	238.89%	-68.00%	1,387.50%	179.83%	-102.40%	962.50%	-34.78%	137.78%	16.82%
Operating Cash Flow Growth	-45.55%	71.06%	20.64%	-78.26%	492.26%	-17.86%	24.01%	-18.40%	64.02%	37.24%
Free Cash Flow Firm Growth	-842.56%	130.27%	-151.45%	-419.81%	265.05%	-14.70%	-149.81%	19.09%	62.08%	-703.36%
Invested Capital Growth	15.46%	2.94%	3.49%	25.69%	51.36%	-8.72%	9.99%	7.65%	8.55%	16.46%
Revenue Q/Q Growth	1.23%	2.61%	2.47%	1.57%	3.30%	-1.94%	3.65%	0.92%	3.51%	5.26%
EBITDA Q/Q Growth	475.21%	135.73%	27.13%	18.45%	10.41%	72.32%	-7.02%	9.41%	3.88%	5.32%
EBIT Q/Q Growth	37.76%	3,253.85%	13.49%	4.79%	-13.82%	422.22%	-12.15%	18.72%	5.14%	4.50%
NOPAT Q/Q Growth	48.45%	1,464.86%	-87.68%	137.12%	479.16%	-200.00%	18.33%	-6.36%	32.88%	3.23%
Net Income Q/Q Growth	39.65%	328.40%	-87.66%	149.40%	331.19%	-102.21%	-9.87%	6.89%	29.64%	3.30%
EPS Q/Q Growth	37.93%	316.67%	-86.67%	147.92%	332.47%	-103.07%	-10.39%	7.14%	30.49%	3.31%
Operating Cash Flow Q/Q Growth	-2.81%	27.65%	0.56%	-68.21%	57.87%	-32.56%	37.91%	27.49%	6.37%	17.00%
Free Cash Flow Firm Q/Q Growth	-10.39%	74.86%	-27.18%	-51.62%	162.43%	179.94%	-485.62%	33.05%	-236.90%	-994.32%
Invested Capital Q/Q Growth	-2.02%	3.01%	-4.75%	6.03%	16.52%	-5.58%	0.69%	-1.18%	2.55%	10.21%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	70.94%	71.09%	71.34%	71.37%	70.98%	65.05%	68.78%	68.81%	69.49%	68.61%
EBITDA Margin	5.87%	14.87%	22.27%	26.08%	20.65%	14.76%	21.40%	21.91%	24.24%	23.43%
Operating Margin	-3.78%	5.33%	14.20%	15.33%	14.14%	-0.81%	10.09%	13.00%	16.45%	15.54%
EBIT Margin	-4.90%	4.89%	12.83%	16.92%	10.81%	2.84%	11.92%	12.70%	15.80%	15.54%
Profit (Net Income) Margin	-3.20%	4.14%	1.15%	17.01%	43.78%	-0.83%	8.76%	5.50%	11.18%	11.02%
Tax Burden Percent	36.77%	196.05%	11.15%	117.51%	684.13%	103.80%	96.75%	61.17%	80.20%	80.89%
Interest Burden Percent	177.60%	43.17%	80.36%	85.56%	59.22%	-28.01%	75.94%	70.83%	88.22%	87.67%
Effective Tax Rate	0.00%	-96.05%	88.75%	-17.51%	-584.13%	0.00%	3.35%	38.83%	19.80%	19.11%
Return on Invested Capital (ROIC)	-1.82%	7.40%	1.18%	12.61%	52.85%	-0.25%	5.11%	4.09%	7.05%	7.01%
ROIC Less NNEP Spread (ROIC-NNEP)	-2.73%	-2.55%	0.42%	11.01%	-15.24%	-0.57%	3.35%	-0.01%	3.51%	4.21%
Return on Net Nonoperating Assets (RNNOA)	-1.92%	-2.08%	0.33%	8.63%	-11.26%	-0.31%	1.41%	-0.01%	1.54%	1.88%
Return on Equity (ROE)	-3.74%	5.32%	1.51%	21.24%	41.59%	-0.56%	6.52%	4.08%	8.58%	8.89%
Cash Return on Invested Capital (CROIC)	-16.17%	4.50%	-2.24%	-10.16%	11.98%	8.87%	-4.41%	-3.28%	-1.15%	-8.20%
Operating Return on Assets (OROA)	-2.08%	2.26%	6.25%	8.30%	4.50%	0.92%	4.50%	4.98%	6.66%	6.99%
Return on Assets (ROA)	-1.36%	1.92%	0.56%	8.35%	18.23%	-0.27%	3.30%	2.16%	4.71%	4.95%
Return on Common Equity (ROCE)	-3.74%	5.32%	1.51%	21.23%	41.59%	-0.56%	6.52%	4.08%	8.52%	8.79%
Return on Equity Simple (ROE_SIMPLE)	-3.78%	5.15%	1.48%	19.15%	33.87%	-0.53%	6.26%	3.97%	8.26%	8.48%
Net Operating Profit after Tax (NOPAT)	-198	876	145	1,770	10,385	-56	1,159	1,009	1,879	2,106
NOPAT Margin	-2.65%	10.45%	1.60%	18.02%	96.74%	-0.56%	9.75%	7.95%	13.20%	12.57%
Net Nonoperating Expense Percent (NNEP)	0.91%	9.94%	0.76%	1.60%	68.09%	0.32%	1.76%	4.10%	3.54%	2.80%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	3.81%	6.56%	6.43%
Cost of Revenue to Revenue	29.06%	28.91%	28.66%	28.64%	29.03%	34.95%	31.22%	31.19%	30.51%	31.39%
SG&A Expenses to Revenue	38.42%	36.95%	36.41%	36.33%	36.71%	38.20%	36.67%	35.64%	36.45%	35.73%
R&D to Revenue	11.72%	10.97%	11.02%	11.33%	10.94%	11.53%	10.13%	10.43%	9.93%	9.64%
Operating Expenses to Revenue	74.72%	65.76%	57.14%	56.03%	56.84%	65.85%	58.70%	55.82%	53.03%	53.07%
Earnings before Interest and Taxes (EBIT)	-366	410	1,161	1,662	1,160	282	1,417	1,611	2,250	2,603
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	439	1,247	2,015	2,562	2,217	1,463	2,544	2,779	3,452	3,923
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.92	4.37	4.86	5.60	4.54	3.36	3.64	3.77	4.39	6.05
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.32	3.51	3.76	4.98	5.87	5.19	5.09	5.23	5.95	7.86
Price to Earnings (P/E)	0.00	84.88	327.32	29.27	13.41	0.00	61.46	103.23	53.94	71.04
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	1.18%	0.31%	3.42%	7.46%	0.00%	1.63%	0.97%	1.85%	1.41%
Enterprise Value to Invested Capital (EV/IC)	2.58	2.89	3.17	3.57	3.08	2.73	2.85	2.90	3.36	4.40
Enterprise Value to Revenue (EV/Rev)	4.03	4.14	4.36	5.68	6.78	5.94	5.69	5.86	6.54	8.49
Enterprise Value to EBITDA (EV/EBITDA)	68.71	27.86	19.59	21.79	32.85	40.26	26.60	26.73	26.99	36.25
Enterprise Value to EBIT (EV/EBIT)	0.00	84.73	34.00	33.58	62.78	208.85	47.76	46.11	41.41	54.63
Enterprise Value to NOPAT (EV/NOPAT)	0.00	39.64	272.93	31.54	7.01	0.00	58.40	73.63	49.58	67.54
Enterprise Value to Operating Cash Flow (EV/OCF)	43.65	29.39	27.68	180.04	39.66	39.06	36.19	48.68	37.23	41.40
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	65.14	0.00	0.00	30.93	29.33	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.90	0.81	0.80	0.81	0.72	0.60	0.55	0.51	0.47	0.49
Long-Term Debt to Equity	0.90	0.81	0.54	0.55	0.62	0.60	0.53	0.51	0.44	0.41
Financial Leverage	0.71	0.82	0.78	0.78	0.74	0.55	0.42	0.44	0.44	0.45
Leverage Ratio	2.75	2.78	2.70	2.54	2.28	2.10	1.97	1.89	1.82	1.79
Compound Leverage Factor	4.89	1.20	2.17	2.18	1.35	-0.59	1.50	1.34	1.61	1.57
Debt to Total Capital	47.32%	44.89%	44.47%	44.71%	41.90%	37.37%	35.29%	33.71%	31.79%	32.81%
Short-Term Debt to Total Capital	0.03%	0.52%	14.26%	14.28%	5.93%	0.05%	1.02%	0.08%	1.85%	5.43%
Long-Term Debt to Total Capital	47.30%	44.36%	30.21%	30.43%	35.97%	37.31%	34.27%	33.63%	29.94%	27.38%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.04%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.87%	0.71%
Common Equity to Total Capital	52.68%	55.11%	55.52%	55.29%	58.10%	62.64%	64.71%	66.30%	67.34%	66.48%
Debt to EBITDA	12.93	4.40	2.79	2.75	4.51	6.25	3.56	3.22	2.64	2.74
Net Debt to EBITDA	12.21	4.24	2.69	2.70	4.42	5.06	2.81	2.88	2.39	2.63
Long-Term Debt to EBITDA	12.92	4.35	1.89	1.87	3.88	6.24	3.46	3.21	2.48	2.29
Debt to NOPAT	-28.66	6.26	38.83	3.99	0.96	-163.27	7.82	8.86	4.84	5.10
Net Debt to NOPAT	-27.05	6.03	37.53	3.90	0.94	-132.30	6.16	7.94	4.38	4.91
Long-Term Debt to NOPAT	-28.64	6.18	26.38	2.71	0.83	-163.04	7.60	8.84	4.56	4.26
Altman Z-Score	0.99	1.41	1.64	2.58	2.63	2.36	2.86	3.26	3.96	5.30
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.01%	0.01%	0.00%	0.00%	-0.01%	-0.01%	0.67%	1.16%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.43	0.90	0.68	0.76	0.97	1.82	1.48	1.51	1.32	1.08
Quick Ratio	0.66	0.47	0.31	0.33	0.42	0.89	0.87	0.76	0.63	0.46
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1,762	533	-274	-1,426	2,354	2,008	-1,000	-809	-307	-2,465
Operating Cash Flow to CapEx	279.76%	340.63%	447.02%	102.65%	404.41%	414.29%	346.30%	264.93%	354.03%	436.47%
Free Cash Flow to Firm to Interest Expense	-6.20	2.29	-1.20	-5.92	4.98	5.56	-2.93	-1.72	-1.16	-8.08
Operating Cash Flow to Interest Expense	2.43	5.07	6.23	1.29	3.88	4.18	5.48	3.25	9.45	11.26
Operating Cash Flow Less CapEx to Interest Expense	1.56	3.58	4.83	0.03	2.92	3.17	3.90	2.02	6.78	8.68
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.43	0.46	0.49	0.49	0.42	0.32	0.38	0.39	0.42	0.45
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	2.22	2.46	2.55	2.51	2.27	2.37	2.51	2.28	2.00	1.99
Fixed Asset Turnover	4.99	5.38	5.44	5.65	5.56	4.76	5.48	5.40	5.37	5.44
Accounts Payable Turnover	9.23	7.39	5.31	6.40	6.99	6.57	5.68	4.78	4.82	5.53
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	164.78	148.39	143.09	145.58	160.77	154.32	145.62	160.40	182.75	183.78
Days Payable Outstanding (DPO)	39.56	49.39	68.76	57.03	52.18	55.57	64.28	76.40	75.77	66.03
Cash Conversion Cycle (CCC)	125.22	99.00	74.32	88.56	108.59	98.76	81.34	84.01	106.98	117.76
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	11,678	12,021	12,440	15,636	23,667	21,603	23,762	25,580	27,766	32,337
Invested Capital Turnover	0.69	0.71	0.74	0.70	0.55	0.44	0.52	0.51	0.53	0.56
Increase / (Decrease) in Invested Capital	1,564	343	419	3,196	8,031	-2,064	2,159	1,818	2,186	4,571
Enterprise Value (EV)	30,163	34,741	39,470	55,814	72,820	58,897	67,674	74,280	93,176	142,207
Market Capitalization	24,805	29,453	34,042	48,904	63,029	51,478	60,534	66,273	84,691	131,642
Book Value per Share	$4.70	$4.94	$5.11	$6.31	$9.96	$10.70	$11.67	$12.27	$13.16	$14.77
Tangible Book Value per Share	($4.72)	($4.28)	($4.24)	($4.02)	($3.00)	($0.38)	($1.04)	($0.87)	($0.76)	($1.36)
Total Capital	11,997	12,217	12,628	15,782	23,885	24,469	25,687	26,508	28,632	32,749
Total Debt	5,677	5,484	5,616	7,056	10,008	9,143	9,065	8,935	9,102	10,746
Total Long-Term Debt	5,674	5,420	3,815	4,803	8,592	9,130	8,804	8,915	8,571	8,968
Net Debt	5,358	5,288	5,428	6,910	9,791	7,409	7,140	8,007	8,237	10,332
Capital Expenditures (CapEx)	247	347	319	302	454	364	540	576	707	787
Debt-free, Cash-free Net Working Capital (DFCFNWC)	725	-480	-219	850	1,032	1,292	379	1,049	1,247	1,885
Debt-free Net Working Capital (DFNWC)	1,044	-284	-31	996	1,249	3,026	2,304	1,977	2,112	2,299
Net Working Capital (NWC)	1,041	-348	-1,832	-1,257	-167	3,013	2,043	1,957	1,581	521
Net Nonoperating Expense (NNE)	41	529	41	99	5,685	26	118	311	287	260
Net Nonoperating Obligations (NNO)	5,358	5,288	5,428	6,910	9,790	6,277	7,140	8,007	8,236	10,334
Total Depreciation and Amortization (D&A)	805	837	854	900	1,057	1,181	1,127	1,168	1,202	1,320
Debt-free, Cash-free Net Working Capital to Revenue	9.70%	-5.72%	-2.42%	8.65%	9.61%	13.03%	3.19%	8.27%	8.76%	11.26%
Debt-free Net Working Capital to Revenue	13.96%	-3.39%	-0.34%	10.14%	11.63%	30.53%	19.38%	15.59%	14.83%	13.73%
Net Working Capital to Revenue	13.92%	-4.15%	-20.25%	-12.80%	-1.56%	30.39%	17.19%	15.43%	11.10%	3.11%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.18)	$0.26	$0.08	$1.21	$3.38	($0.08)	$0.69	$0.45	$1.08	$1.26
Adjusted Weighted Average Basic Shares Outstanding	1.34B	1.36B	1.37B	1.38B	1.39B	1.42B	1.42B	1.43B	1.45B	1.47B
Adjusted Diluted Earnings per Share	($0.18)	$0.25	$0.08	$1.19	$3.33	($0.08)	$0.69	$0.45	$1.07	$1.25
Adjusted Weighted Average Diluted Shares Outstanding	1.34B	1.38B	1.39B	1.40B	1.41B	1.42B	1.43B	1.44B	1.46B	1.49B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$3.38	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.35B	1.36B	1.37B	1.39B	1.40B	1.42B	1.43B	1.43B	1.47B	1.48B
Normalized Net Operating Profit after Tax (NOPAT)	693	923	1,072	1,161	1,219	478	1,839	1,231	1,938	2,427
Normalized NOPAT Margin	9.27%	11.01%	11.84%	11.82%	11.35%	4.82%	15.47%	9.71%	13.61%	14.49%
Pre Tax Income Margin	-8.69%	2.11%	10.31%	14.48%	6.40%	-0.80%	9.05%	9.00%	13.94%	13.63%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-1.29	1.76	5.07	6.90	2.45	0.78	4.16	3.43	8.49	8.53
NOPAT to Interest Expense	-0.70	3.76	0.63	7.34	21.96	-0.16	3.40	2.15	7.09	6.90
EBIT Less CapEx to Interest Expense	-2.16	0.27	3.68	5.64	1.49	-0.23	2.57	2.20	5.82	5.95
NOPAT Less CapEx to Interest Expense	-1.57	2.27	-0.76	6.09	21.00	-1.16	1.81	0.92	4.42	4.32
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-34.15%	5.28%	7.88%	1.76%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-686.59%	5.28%	7.88%	1.76%	0.00%

This table displays calculated financial ratios and metrics derived from Boston Scientific's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	8.12%	3.68%	12.00%	10.94%	11.26%	14.90%	13.78%	14.48%	19.34%	22.47%	20.93%
EBITDA Growth	-29.40%	46.41%	9.37%	13.27%	63.55%	17.11%	23.55%	1.76%	7.67%	21.63%	31.80%
EBIT Growth	-45.95%	123.30%	17.01%	21.27%	119.87%	23.91%	33.01%	0.20%	10.67%	18.42%	31.02%
NOPAT Growth	-18.17%	-0.51%	17.36%	2.19%	108.84%	312.01%	40.65%	22.38%	-10.43%	11.26%	40.47%
Net Income Growth	-55.13%	47.37%	185.45%	3.85%	168.09%	260.00%	57.01%	19.26%	-7.14%	11.71%	36.31%
EPS Growth	-57.14%	50.00%	200.00%	5.88%	183.33%	277.78%	57.14%	22.22%	-5.88%	11.76%	36.36%
Operating Cash Flow Growth	1.08%	68.83%	427.59%	114.33%	48.51%	18.59%	-13.68%	23.56%	43.55%	52.14%	229.88%
Free Cash Flow Firm Growth	-423.39%	16.87%	82.99%	74.19%	69.36%	4.38%	-210.70%	9.76%	-184.14%	-144.68%	-178.28%
Invested Capital Growth	9.69%	7.65%	3.22%	4.49%	4.60%	8.55%	7.21%	4.26%	8.37%	16.46%	16.07%
Revenue Q/Q Growth	-2.28%	2.27%	4.53%	6.20%	-2.00%	5.61%	3.52%	6.85%	2.16%	8.39%	2.21%
EBITDA Q/Q Growth	-14.69%	26.09%	5.31%	0.00%	23.17%	-9.71%	11.10%	-17.64%	30.32%	1.99%	20.39%
EBIT Q/Q Growth	-24.94%	49.84%	10.65%	-2.55%	36.09%	-15.56%	18.77%	-26.59%	50.30%	-9.64%	31.41%
NOPAT Q/Q Growth	-13.83%	-48.50%	175.08%	-16.28%	76.11%	1.59%	-6.09%	-27.16%	28.90%	26.19%	18.56%
Net Income Q/Q Growth	-27.69%	-25.53%	124.29%	-14.01%	86.67%	0.00%	-2.18%	-34.69%	45.34%	20.30%	19.36%
EPS Q/Q Growth	-29.41%	-25.00%	133.33%	-14.29%	88.89%	0.00%	-2.94%	-33.33%	45.45%	18.75%	18.42%
Operating Cash Flow Q/Q Growth	53.09%	71.70%	-76.46%	246.32%	6.08%	37.11%	-82.86%	395.73%	23.25%	45.31%	-62.84%
Free Cash Flow Firm Q/Q Growth	38.14%	16.64%	73.76%	-90.79%	26.56%	-160.13%	14.75%	44.59%	-131.22%	-124.00%	3.04%
Invested Capital Q/Q Growth	-0.24%	-1.18%	3.77%	2.14%	-0.14%	2.55%	2.49%	-0.67%	3.79%	10.21%	2.14%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	69.12%	68.85%	69.31%	70.63%	68.78%	69.23%	68.67%	69.17%	68.83%	67.84%	68.84%
EBITDA Margin	18.86%	23.26%	23.43%	22.06%	27.73%	23.70%	25.44%	19.61%	25.02%	23.54%	27.73%
Operating Margin	11.29%	12.40%	16.29%	14.28%	19.65%	15.68%	17.51%	12.62%	17.42%	14.80%	19.75%
EBIT Margin	9.68%	14.19%	15.02%	13.78%	19.14%	15.30%	17.56%	12.06%	17.75%	14.80%	19.02%
Profit (Net Income) Margin	5.93%	4.32%	9.27%	7.50%	14.29%	13.53%	12.79%	7.82%	11.12%	12.34%	14.41%
Tax Burden Percent	76.73%	35.44%	70.72%	63.38%	82.62%	99.80%	81.09%	76.67%	69.96%	96.24%	83.48%
Interest Burden Percent	79.80%	85.87%	87.23%	85.89%	90.37%	88.60%	89.81%	84.51%	89.56%	86.67%	90.76%
Effective Tax Rate	23.27%	64.81%	29.50%	36.62%	17.21%	0.20%	18.91%	23.33%	29.90%	3.93%	16.52%
Return on Invested Capital (ROIC)	4.40%	2.24%	5.73%	4.57%	8.45%	8.35%	7.59%	5.32%	6.89%	7.92%	9.41%
ROIC Less NNEP Spread (ROIC-NNEP)	3.27%	2.22%	4.87%	3.93%	7.59%	7.38%	6.94%	4.38%	6.32%	7.00%	8.39%
Return on Net Nonoperating Assets (RNNOA)	1.48%	0.99%	2.43%	1.90%	3.34%	3.23%	3.03%	1.82%	2.58%	3.13%	3.72%
Return on Equity (ROE)	5.88%	3.23%	8.17%	6.48%	11.79%	11.59%	10.62%	7.15%	9.46%	11.05%	13.13%
Cash Return on Invested Capital (CROIC)	-4.89%	-3.28%	1.01%	-0.24%	0.85%	-1.15%	0.43%	3.42%	-0.80%	-8.20%	-7.30%
Operating Return on Assets (OROA)	3.81%	5.56%	6.01%	5.61%	7.98%	6.45%	7.42%	5.20%	7.83%	6.65%	8.69%
Return on Assets (ROA)	2.34%	1.69%	3.71%	3.06%	5.96%	5.70%	5.41%	3.37%	4.91%	5.55%	6.59%
Return on Common Equity (ROCE)	5.88%	3.23%	8.11%	6.43%	11.71%	11.51%	10.48%	7.06%	9.35%	10.92%	12.98%
Return on Equity Simple (ROE_SIMPLE)	3.70%	0.00%	5.05%	5.00%	6.50%	0.00%	8.89%	8.95%	8.63%	0.00%	9.12%
Net Operating Profit after Tax (NOPAT)	275	141	389	326	574	583	547	399	514	648	769
NOPAT Margin	8.67%	4.36%	11.48%	9.05%	16.27%	15.65%	14.19%	9.68%	12.21%	14.21%	16.49%
Net Nonoperating Expense Percent (NNEP)	1.13%	0.02%	0.86%	0.64%	0.86%	0.97%	0.65%	0.94%	0.56%	0.92%	1.03%
Return On Investment Capital (ROIC_SIMPLE)	-	0.53%	-	-	-	2.04%	-	-	-	1.98%	2.28%
Cost of Revenue to Revenue	30.88%	31.18%	30.69%	29.40%	31.22%	30.77%	31.35%	30.83%	31.17%	32.14%	31.16%
SG&A Expenses to Revenue	35.71%	35.87%	35.85%	37.62%	35.21%	37.02%	35.37%	35.10%	37.11%	35.34%	34.25%
R&D to Revenue	10.69%	10.18%	9.94%	9.98%	10.09%	9.72%	9.49%	9.30%	9.67%	10.06%	9.50%
Operating Expenses to Revenue	57.82%	56.48%	53.02%	56.35%	49.14%	53.53%	51.17%	56.55%	51.41%	53.05%	49.07%
Earnings before Interest and Taxes (EBIT)	307	460	509	496	675	570	677	497	747	675	887
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	598	754	794	794	978	883	981	808	1,053	1,074	1,293
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.14	3.77	4.02	4.27	4.09	4.39	0.00	5.56	5.96	6.05	6.70
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	202.90	0.00	0.00	0.00
Price to Revenue (P/Rev)	4.41	5.23	5.50	5.80	5.62	5.95	0.00	7.43	7.76	7.86	8.48
Price to Earnings (P/E)	92.88	103.23	84.85	90.32	64.86	53.94	0.00	61.94	68.87	71.04	73.27
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.08%	0.97%	1.18%	1.11%	1.54%	1.85%	0.00%	1.61%	1.45%	1.41%	1.36%
Enterprise Value to Invested Capital (EV/IC)	2.46	2.90	3.03	3.20	3.16	3.36	0.00	4.28	4.50	4.40	4.83
Enterprise Value to Revenue (EV/Rev)	5.07	5.86	6.17	6.47	6.22	6.54	0.00	7.95	8.30	8.49	9.10
Enterprise Value to EBITDA (EV/EBITDA)	25.08	26.73	28.42	29.44	25.73	26.99	0.00	33.18	35.45	36.25	37.39
Enterprise Value to EBIT (EV/EBIT)	46.94	46.11	47.76	48.90	39.95	41.41	0.00	50.07	53.01	54.63	56.05
Enterprise Value to NOPAT (EV/NOPAT)	59.12	73.63	73.65	78.74	60.46	49.58	0.00	57.56	64.73	67.54	68.62
Enterprise Value to Operating Cash Flow (EV/OCF)	53.21	48.68	45.36	40.78	36.34	37.23	0.00	46.02	44.97	41.40	41.89
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	305.15	0.00	381.43	0.00	0.00	127.75	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.49	0.51	0.50	0.49	0.47	0.47	0.53	0.51	0.52	0.49	0.50
Long-Term Debt to Equity	0.49	0.51	0.47	0.46	0.44	0.44	0.47	0.44	0.44	0.41	0.47
Financial Leverage	0.45	0.44	0.50	0.48	0.44	0.44	0.44	0.42	0.41	0.45	0.44
Leverage Ratio	1.87	1.89	1.87	1.84	1.79	1.82	1.82	1.81	1.80	1.79	1.80
Compound Leverage Factor	1.49	1.62	1.63	1.58	1.62	1.61	1.63	1.53	1.61	1.56	1.64
Debt to Total Capital	32.73%	33.71%	33.21%	32.87%	31.75%	31.79%	34.49%	33.90%	34.19%	32.81%	33.50%
Short-Term Debt to Total Capital	0.08%	0.08%	1.88%	2.03%	1.83%	1.85%	3.52%	5.07%	5.19%	5.43%	2.30%
Long-Term Debt to Total Capital	32.66%	33.63%	31.33%	30.84%	29.92%	29.94%	30.97%	28.84%	29.00%	27.38%	31.20%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.96%	0.94%	0.87%	0.87%	0.79%	0.76%	0.78%	0.71%	0.69%
Common Equity to Total Capital	67.27%	66.30%	65.83%	66.18%	67.38%	67.34%	64.72%	65.34%	65.04%	66.48%	65.80%
Debt to EBITDA	3.38	3.22	3.18	3.08	2.68	2.64	2.92	2.90	2.92	2.74	2.65
Net Debt to EBITDA	3.25	2.88	2.98	2.93	2.39	2.39	2.28	2.10	2.25	2.63	2.48
Long-Term Debt to EBITDA	3.37	3.21	3.00	2.89	2.52	2.48	2.62	2.46	2.48	2.29	2.47
Debt to NOPAT	7.97	8.86	8.24	8.23	6.29	4.84	5.22	5.02	5.34	5.10	4.86
Net Debt to NOPAT	7.65	7.94	7.72	7.84	5.62	4.38	4.08	3.64	4.11	4.91	4.55
Long-Term Debt to NOPAT	7.95	8.84	7.77	7.72	5.93	4.56	4.69	4.27	4.53	4.26	4.53
Altman Z-Score	2.77	3.15	3.40	3.57	3.66	3.80	0.00	4.74	4.97	5.13	5.74
Noncontrolling Interest Sharing Ratio	0.00%	-0.01%	0.74%	0.72%	0.66%	0.67%	1.31%	1.27%	1.23%	1.16%	1.12%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.45	1.51	1.40	1.29	1.42	1.32	1.67	1.61	1.48	1.08	1.45
Quick Ratio	0.62	0.76	0.65	0.56	0.67	0.63	0.94	0.95	0.85	0.46	0.68
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-2,011	-1,677	-440	-839	-616	-1,603	-1,367	-757	-1,751	-3,923	-3,803
Operating Cash Flow to CapEx	315.44%	384.29%	175.93%	460.14%	369.31%	358.43%	92.13%	524.52%	559.78%	529.45%	289.30%
Free Cash Flow to Firm to Interest Expense	-31.93	-26.20	-6.77	-11.99	-9.34	-25.05	-19.81	-9.84	-22.17	-49.03	-46.38
Operating Cash Flow to Interest Expense	7.46	12.61	2.92	9.40	10.58	14.95	2.38	10.56	12.68	18.20	6.60
Operating Cash Flow Less CapEx to Interest Expense	5.10	9.33	1.26	7.36	7.71	10.78	-0.20	8.55	10.42	14.76	4.32
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.39	0.39	0.40	0.41	0.42	0.42	0.42	0.43	0.44	0.45	0.46
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	2.31	2.28	2.13	2.04	2.01	2.00	1.96	1.95	1.91	1.99	2.03
Fixed Asset Turnover	5.74	5.40	5.50	5.61	5.61	5.37	5.47	5.55	5.58	5.44	5.59
Accounts Payable Turnover	5.30	4.78	5.17	5.01	4.86	4.82	5.05	5.24	5.38	5.53	5.72
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	157.99	160.40	170.98	178.66	181.72	182.75	186.42	187.60	190.63	183.78	180.08
Days Payable Outstanding (DPO)	68.82	76.40	70.63	72.81	75.08	75.77	72.33	69.70	67.87	66.03	63.86
Cash Conversion Cycle (CCC)	89.18	84.01	100.35	105.85	106.64	106.98	114.09	117.90	122.76	117.76	116.21
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	25,885	25,580	26,544	27,112	27,075	27,766	28,458	28,268	29,340	32,337	33,030
Invested Capital Turnover	0.51	0.51	0.50	0.51	0.52	0.53	0.53	0.55	0.56	0.56	0.57
Increase / (Decrease) in Invested Capital	2,286	1,818	829	1,165	1,190	2,186	1,914	1,156	2,265	4,571	4,572
Enterprise Value (EV)	63,692	74,280	80,476	86,651	85,501	93,176	0.00	121,115	132,037	142,207	159,693
Market Capitalization	55,446	66,273	71,782	77,765	77,311	84,691	0.00	113,219	123,406	131,642	148,876
Book Value per Share	$12.32	$12.27	$12.44	$12.68	$12.90	$13.16	$13.57	$13.86	$14.06	$14.77	$15.05
Tangible Book Value per Share	($0.89)	($0.87)	($1.03)	($1.04)	($0.39)	($0.76)	($0.19)	$0.38	($0.05)	($1.36)	($1.15)
Total Capital	26,224	26,508	27,114	27,538	28,028	28,632	30,787	31,180	31,841	32,749	33,755
Total Debt	8,584	8,935	9,005	9,053	8,899	9,102	10,619	10,571	10,885	10,746	11,309
Total Long-Term Debt	8,564	8,915	8,495	8,494	8,386	8,571	9,534	8,991	9,233	8,968	10,532
Net Debt	8,246	8,007	8,435	8,627	7,947	8,237	8,290	7,658	8,383	10,332	10,584
Capital Expenditures (CapEx)	149	210	108	143	189	267	178	155	179	275	187
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,277	1,049	1,561	1,457	1,486	1,247	2,025	2,082	2,001	1,885	2,329
Debt-free Net Working Capital (DFNWC)	1,615	1,977	2,131	1,883	2,438	2,112	4,354	4,995	4,503	2,299	3,054
Net Working Capital (NWC)	1,595	1,957	1,621	1,324	1,925	1,581	3,269	3,415	2,851	521	2,277
Net Nonoperating Expense (NNE)	87	1.46	75	56	70	79	54	77	46	85	97
Net Nonoperating Obligations (NNO)	8,245	8,007	8,435	8,627	7,946	8,236	8,290	7,659	8,384	10,334	10,584
Total Depreciation and Amortization (D&A)	291	294	285	298	303	313	304	311	306	399	406
Debt-free, Cash-free Net Working Capital to Revenue	10.16%	8.27%	11.97%	10.87%	10.80%	8.76%	13.77%	13.67%	12.58%	11.26%	13.27%
Debt-free Net Working Capital to Revenue	12.85%	15.59%	16.34%	14.05%	17.72%	14.83%	29.61%	32.80%	28.30%	13.73%	17.40%
Net Working Capital to Revenue	12.69%	15.43%	12.43%	9.88%	13.99%	11.10%	22.23%	22.43%	17.92%	3.11%	12.97%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.12	$0.09	$0.21	$0.18	$0.34	$0.35	$0.34	$0.22	$0.32	$0.38	$0.46
Adjusted Weighted Average Basic Shares Outstanding	1.43B	1.43B	1.44B	1.45B	1.46B	1.45B	1.47B	1.47B	1.47B	1.47B	1.48B
Adjusted Diluted Earnings per Share	$0.12	$0.09	$0.21	$0.18	$0.34	$0.34	$0.33	$0.22	$0.32	$0.38	$0.45
Adjusted Weighted Average Diluted Shares Outstanding	1.44B	1.44B	1.45B	1.46B	1.48B	1.46B	1.48B	1.48B	1.49B	1.49B	1.49B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.43B	1.43B	1.44B	1.46B	1.46B	1.47B	1.47B	1.47B	1.47B	1.48B	1.48B
Normalized Net Operating Profit after Tax (NOPAT)	389	354	412	384	505	616	564	613	503	651	781
Normalized NOPAT Margin	12.27%	10.90%	12.15%	10.67%	14.32%	16.53%	14.61%	14.87%	11.96%	14.28%	16.76%
Pre Tax Income Margin	7.73%	12.18%	13.10%	11.84%	17.30%	13.56%	15.77%	10.19%	15.89%	12.82%	17.26%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	4.87	7.19	7.83	7.09	10.23	8.91	9.81	6.45	9.46	8.44	10.82
NOPAT to Interest Expense	4.36	2.21	5.99	4.65	8.69	9.11	7.93	5.18	6.50	8.11	9.38
EBIT Less CapEx to Interest Expense	2.51	3.91	6.17	5.04	7.36	4.73	7.23	4.44	7.19	5.00	8.54
NOPAT Less CapEx to Interest Expense	2.00	-1.07	4.33	2.61	5.83	4.94	5.35	3.16	4.24	4.67	7.10
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	8.42%	7.88%	6.10%	6.03%	3.34%	1.76%	0.79%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	8.42%	7.88%	6.10%	6.03%	3.34%	1.76%	0.79%	0.00%	0.00%	0.00%	0.00%

Key Financial Trends

Boston Scientific (NYSE: BSX) has exhibited steady growth over the past four years through Q1 2025, with several key financial trends worth highlighting:

Revenue Growth: Operating revenue has risen from approximately $3.39 billion in Q1 2023 to $4.66 billion in Q1 2025, reflecting a consistent increase in sales and operational scale.
Increasing Net Income: Net income attributable to common shareholders increased from $300 million in Q1 2023 to $674 million in Q1 2025, which underlines improved profitability.
Solid Gross Profit Margins: Gross profit increased from about $2.35 billion in Q1 2023 to $3.21 billion in Q1 2025, indicating effective management of cost of revenue relative to sales growth.
Consistent R&D Investment: Research and development expenses remain robust, around $337 million in Q1 2023 to $443 million in Q1 2025, demonstrating commitment to innovation.
Strong Operating Income Growth: Operating income expanded notably from $552 million (Q1 2023) to $921 million (Q1 2025), showing operational efficiency improvements.
Improving Earnings Per Share (EPS): Adjusted diluted EPS increased from $0.21 in Q1 2023 to $0.45 in Q1 2025, reflecting bottom-line growth alongside controlled share count increases.
Debt Management: Long-term debt increased from about $8.5 billion in Q1 2023 to $10.5 billion in Q1 2025, indicating Boston Scientific is leveraging debt potentially for growth, which requires monitoring.
Capex and Acquisitions: Capital expenditures and acquisitions remain sizeable (e.g., approximately $187 million property purchases and $239 million in acquisitions in Q1 2025) supporting growth, but increasing capital demands.
Cash Position Strengthened: Cash and equivalents rose to $725 million in Q1 2025 from $570 million in Q1 2023, improving liquidity.
Rising Operating Expenses: Selling, General & Admin expenses increased from ~$1.2 billion in Q1 2023 to $1.6 billion in Q1 2025, which partially offsets gross profit gains and pressures margins.

Summary: Boston Scientific has demonstrated solid revenue and earnings growth from 2022 through early 2025, supported by ongoing investments in R&D and strategic acquisitions. Operating income and EPS improvements underscore efficient scaling of operations. However, increases in SG&A expenses and higher debt levels highlight areas investors should watch to assess sustainable profitability and financial risk. Overall, the financial trajectory is positive with continued expansion indicating growth potential.

08/05/25 02:48 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Boston Scientific's Financials

When does Boston Scientific's financial year end?

According to the most recent income statement we have on file, Boston Scientific's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Boston Scientific's net income changed over the last 9 years?

Boston Scientific's net income appears to be on an upward trend, with a most recent value of $1.85 billion in 2024, falling from -$239 million in 2015. The previous period was $1.59 billion in 2023. Find out what analysts predict for Boston Scientific in the coming months.

What is Boston Scientific's operating income?

Boston Scientific's total operating income in 2024 was $2.60 billion, based on the following breakdown:

Total Gross Profit: $11.49 billion
Total Operating Expenses: $8.89 billion

How has Boston Scientific's revenue changed over the last 9 years?

Over the last 9 years, Boston Scientific's total revenue changed from $7.48 billion in 2015 to $16.75 billion in 2024, a change of 124.0%.

How much debt does Boston Scientific have?

Boston Scientific's total liabilities were at $17.39 billion at the end of 2024, a 11.5% increase from 2023, and a 47.2% increase since 2015.

How much cash does Boston Scientific have?

In the past 9 years, Boston Scientific's cash and equivalents has ranged from $146 million in 2018 to $1.93 billion in 2021, and is currently $414 million as of their latest financial filing in 2024.

How has Boston Scientific's book value per share changed over the last 9 years?

Over the last 9 years, Boston Scientific's book value per share changed from 4.70 in 2015 to 14.77 in 2024, a change of 214.4%.

Related Companies

This page (NYSE:BSX) was last updated on 8/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Boston Scientific (BSX) Financials

Key Financial Trends

Frequently Asked Questions About Boston Scientific's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Boston Scientific (BSX) Financials

Annual Income Statements for Boston Scientific

Quarterly Income Statements for Boston Scientific

Annual Cash Flow Statements for Boston Scientific

Quarterly Cash Flow Statements for Boston Scientific

Annual Balance Sheets for Boston Scientific

Quarterly Balance Sheets for Boston Scientific

Annual Metrics And Ratios for Boston Scientific

Quarterly Metrics And Ratios for Boston Scientific

Key Financial Trends

Frequently Asked Questions About Boston Scientific's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools